MaaT Pharma Provides Third Quarter 2024 Business and Financial Results

• Completion of enrollment in the European Phase 3 clinical trial ARES designed to evaluate efficacy and safety of MaaT013 in the treatment of acute Graft-versus-Host Disease; topline results expected in January 2025.
• Positive safety assessment by first DSMB of the European Phase 2b trial PHOEBUS with the DSMB recommending continuation of the trial without modification.
• As of September 30, 2024, cash and cash equivalents were EUR 27 million[1].
• Revenues of EUR 0.6 million in Q3 2024 compared with EUR 0.4 million in Q3 2023. This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013.
• Nomination of Eric Soyer as Chief Financial Officer and transition of Sian Crouzet to Chief of Staff, after 8 years as Chief Financial Officer.

Read the press release